Vanguard Group’s Guardion Health Sciences, Inc. Common Stock GHSI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-14,852
| Closed | -$82.3K | – | 4369 |
|
|
2024
Q3 | $82.3K | Hold |
14,852
| – | – | ﹤0.01% | 4214 |
|
|
2024
Q2 | $149K | Hold |
14,852
| – | – | ﹤0.01% | 4195 |
|
|
2024
Q1 | $134K | Hold |
14,852
| – | – | ﹤0.01% | 4217 |
|
|
2023
Q4 | $79.3K | Hold |
14,852
| – | – | ﹤0.01% | 4324 |
|
|
2023
Q3 | $110K | Buy |
+14,852
| New | +$114K | ﹤0.01% | 4339 |
|
|
2023
Q1 | – | Sell |
-5,766
| Closed | -$41.8K | – | 4584 |
|
|
2022
Q4 | $41.8K | Hold |
5,766
| – | – | ﹤0.01% | 4457 |
|
|
2022
Q3 | $39K | Sell |
5,766
-15,755
| -73% | -$120K | ﹤0.01% | 4568 |
|
|
2022
Q2 | $155K | Hold |
21,521
| – | – | ﹤0.01% | 4495 |
|
|
2022
Q1 | $249K | Hold |
21,521
| – | – | ﹤0.01% | 4506 |
|
|
2021
Q4 | $697K | Buy |
21,521
+32
| +0.1% | +$1.72K | ﹤0.01% | 4364 |
|
|
2021
Q3 | $1.36M | Buy |
21,489
+93
| +0.4% | +$6.18K | ﹤0.01% | 4170 |
|
|
2021
Q2 | $1.88M | Buy |
21,396
+9,717
| +83% | +$844K | ﹤0.01% | 3977 |
|
|
2021
Q1 | $1.4M | Buy |
11,679
+1,502
| +15% | +$303K | ﹤0.01% | 3937 |
|
|
2020
Q4 | $1.27M | Buy |
10,177
+699
| +7% | +$48.8K | ﹤0.01% | 3770 |
|
|
2020
Q3 | $570K | Buy |
9,478
+7,183
| +313% | +$744K | ﹤0.01% | 3787 |
|
|
2020
Q2 | $302K | Buy |
2,295
+470
| +26% | +$65.5K | ﹤0.01% | 3865 |
|
|
2020
Q1 | $249K | Buy |
1,825
+1,685
| +1,204% | +$178K | ﹤0.01% | 3825 |
|
|
2019
Q4 | $9K | Buy |
+140
| New | +$13.4K | ﹤0.01% | 4119 |
|
Vanguard Group's GHSI Position: Q4 2024 in Review
Vanguard Group sold out of Guardion Health Sciences, Inc. Common Stock (GHSI) in Q4 2024, closing a stake of 14,852 shares — an estimated $82.3K sold.
Vanguard Group first reported a position in GHSI in Q4 2019 and held it in 18 quarters. The position peaked at $1.88M in Q2 2021. 0 funds tracked by Wall St. Rank hold GHSI as of Q4 2024.
- Vanguard Group reported no remaining Guardion Health Sciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Vanguard Group sold 14,852 Guardion Health Sciences, Inc. Common Stock shares in Q4 2024, an estimated $82.3K.
- Vanguard Group first reported a position in Guardion Health Sciences, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Vanguard Group's Guardion Health Sciences, Inc. Common Stock position peaked at $1.88M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Guardion Health Sciences, Inc. Common Stock as of Q4 2024.
Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.